Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Maraviroc,Atorvastatin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HealthBioAI Receives FDA Acceptance for Long COVID Trial with Selzentry® and Lipitor
Details : Selzentry (maraviroc) is a CCR5 co-receptor antagonist, in combination with Lipitor (atorvastatin) is being evaluated for the treatment of Long COVID/Post Acute Sequelae of COVID.
Product Name : Selzentry
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Maraviroc,Atorvastatin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Atorvaliq (atorvastatin calcium) is the first and only FDA-approved oral liquid Suspension that is indicated for the treatment of high cholesterol and certain risk factors for heart disease or stroke.
Product Name : Atorvaliq
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2023
Lead Product(s) : Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Obicetrapib,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Frazier Healthcare Partners
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Treatment with TA-8995 (obicetrapib) in patients on high-intensity statin therapy was observed to have statistically significant impact on LDL-C, as well as significant impacts on ApoB, non-HDL-C, HDL-C and Lp(a), additional key measures of cardiovascula...
Product Name : TA-8995
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 08, 2022
Lead Product(s) : Obicetrapib,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Frazier Healthcare Partners
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apabetalone,Atorvastatin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : RVX-208
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2022
Lead Product(s) : Apabetalone,Atorvastatin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bempedoic Acid,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The aim of this Phase 2 study was to evaluate LDL-C lowering when NEXLETOL was initiated together with ezetimibe (10 mg) and atorvastatin (20 mg), as compared with placebo.
Product Name : Nexletol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2021
Lead Product(s) : Bempedoic Acid,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Astellas Pharma
Deal Size : Undisclosed
Deal Type : Termination
Astellas Announces Termination of Co-promotion Agreement with Viatris for Lipitor® Tablets
Details : Astellas and Viatris have agreed to end the co-promotion of a hypercholesterolemia and familial hypercholesterolemia treatment “Lipitor® Tablets 5mg, 10mg” manufactured and sold by Astellas.
Product Name : Lipitor
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 04, 2021
Lead Product(s) : Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Astellas Pharma
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Atorvastatin,Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Indication Bioscience Granted First Patent for Statin Plus Cannabidiol (CBD) Combination
Details : The U.S. Patent covers pharmaceutical compositions comprising a statin and a cannabinoid, and their use for the treatment of hypercholesterolemia and atherosclerosis.
Product Name : Atrova+
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 02, 2021
Lead Product(s) : Atorvastatin,Cannabidiol
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amlodipine,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Viatris
Deal Size : $12,000.0 million
Deal Type : Merger
Pfizer Completes Transaction to Combine Its Upjohn Business with Mylan
Details : Pfizer and Mylan have received clearance from the US FTC to advance the merger of Pfizer’s Upjohn generics unit and Mylan. As part of the FTC clearance, the companies need to divest seven products before moving forward with the merger, this includes Up...
Product Name : Caduet
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 16, 2020
Lead Product(s) : Amlodipine,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Viatris
Deal Size : $12,000.0 million
Deal Type : Merger
Lead Product(s) : Apabetalone,Atorvastatin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : RVX-208
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 06, 2020
Lead Product(s) : Apabetalone,Atorvastatin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apabetalone,Atorvastatin
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Resverlogix Reaches Agreement With FDA for Key Aspects of Apabetalone Registration Enabling Study
Details :
Product Name : RVX-208
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2020
Lead Product(s) : Apabetalone,Atorvastatin
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable